Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > REGULATORY
REGULATORY
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- Japan Launches Omicron Booster Program for COVID-19
September 21, 2022
- MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- Japan OKs Additional Indications for 12 Fertility Treatments
September 20, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
- Japan’s Omicron Booster Program to Get Underway on Sept. 20
September 15, 2022
- MHLW to Simplify Optimal-Use Guidelines for Drugs after Reexamination Period
September 15, 2022
- Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors
September 14, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…